echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The development of traditional Chinese medicine in modern scientific and technological innovation urgently needs strong support from national policies.

    The development of traditional Chinese medicine in modern scientific and technological innovation urgently needs strong support from national policies.

    • Last Update: 2020-09-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Introduction: The development of modern scientific and technological innovation of Chinese medicine urgently needs the strong support of national policies, stimulate the enthusiasm of Chinese medicine enterprises for research and development, the initiative of innovation firmly in their own hands, and effectively leave the ancestors of Chinese medicine to our precious wealth inherited, developed and applied well, so that Chinese medicine for the better benefit of mankind.
    The Party and the government attach great importance to the work of Chinese medicine, with Comrade Xi Jinping as its core, put the work of Chinese medicine in a more prominent position, and in October 2019, the State Council issued the Opinions on Promoting the Innovation and Development of Chinese Medicine Heritage, re-emphasizing the need to promote the innovation and development of Chinese medicine heritage.
    , however, modern scientific and technological innovation chinese medicine is facing the transformation of the concept of value brought about by the transformation of "pain" and "green and yellow do not connect" dilemma.
    investment, health insurance price reduction, cost is difficult to collect, enterprise enthusiasm is not high innovation of Chinese medicine investment, long research and development cycle, high cost, low return on research and development.
    Generally, a new Chinese medicine takes 10-20 years, an average of 15 years; When the medical insurance catalog, after the modernization of the purification process of innovative Chinese medicine to the catalog of traditional chinese medicine price, if you can not enter the health insurance is equal to the market, drugs can not be sold, enterprises in order to enter the medical insurance catalog and significantly reduce prices, it will be difficult to recover costs;
    has not been included in the national list of essential drugs, the development of serious constraints in December 2019, the National Health and Construction Commission issued "on doing a good job in medical institutions reasonable drug assessment notice", clear "base drug 986" equipment requirements, to ensure the use of basic drug products;
    the same time, the performance appraisal of national public hospitals involves reasonable drug use index, which seriously affects the initial sales of innovative drugs entering the base drug catalogue.
    this makes the early market development of innovative Chinese medicine seriously restricted.
    Lack of policy support, innovative Chinese medicine advantages difficult to play although the state greatly increased support for the Chinese medicine industry to promote the inheritance and innovation of Chinese medicine, but for the injection of modern scientific and technological connotation of innovative Chinese medicine a series of related issues have not been treated differently, such as access to medical insurance prices, post-market pricing, patent protection, international standards and channels, and other issues, the relevant departments of the national government from the top-level design to give more attention to innovative Chinese medicine, multi-pronged, strong support.
    recent instructions from national leaders that innovation initiatives and development initiatives must be firmly in their own hands.
    The author believes that innovative Chinese medicine can be supported from the following four aspects: First, the National Health Insurance Administration of innovative Chinese medicine can take "priority inclusion, sequent order bargaining" strategy of new drugs just listed within three years belong to the product import period, even if entering the medical insurance catalog, market acceptance takes a certain amount of time, hospital access also has great difficulties.
    because of low sales in the early market, the pre-product pricing has little impact on health insurance funds.
    suggested that when the new Chinese medicine has just come on the market, the State Health Insurance Administration can and enterprises according to drug sales agreed health insurance access prices, the early use of high prices to compensate, followed by sales growth proportionally reduce pricing.
    To "A medicine" as an example: Table 1 "A drug" market forecast for the next 3 years Table 2 "A drug" drug sales amount and pricing range hypothesis for innovative Chinese medicine to adopt a "priority inclusion, sequentdined bargaining" strategy, not only to enable innovative Chinese medicine to be included in the health insurance catalog as soon as possible, but also to ensure that the variety in the recovery of costs at the same time have reasonable profit margins, thereby enhancing the enthusiasm of enterprise innovation.
    second, the National Health and Safety Commission can be eligible for innovative Chinese medicine as soon as possible into the national basic drug catalog for those with chemical drugs for head-to-head comparative research, clear efficacy, high safety of modern scientific and technological innovation chinese medicine, can be included in the national basic drug catalog as soon as possible, and does not take into account the proportion of drug performance Assessment category (at present, Liaoning Province has begun to implement the national basic drugs are not included in the public hospital drug proportion calculation category pilot), so that innovative Chinese medicine can quickly enter the hospital, increase market sales, so that more patients use such good medicine, accelerate the promotion of Chinese medicine research and innovation, improve the transformation of chinese medicine research and innovation capacity.
    Third, the State Health Insurance Administration, the National Health Care Commission and the State Drug Administration should add "natural Chinese medicine" drug classification in their respective drug catalogues China has a wealth of natural plant resources, modern science and technology and traditional Chinese medicine theory combined, research and development of internationally recognized modern natural medicine, is undoubtedly China's original breakthrough point.
    But at present, the catalogue of medicines of various ministries and departments of the state is classified according to Chinese medicine, chemical medicine and biological medicine, among which, Chinese medicine refers to Chinese medicine described according to dialectical treatment, and chemical medicine is described according to different mechanisms of action.
    it is unreasonable to conduct clinical studies and approved drugs according to natural drugs, whether compared with traditional Chinese medicine or directly compared with chemical drugs, and should be considered for separate classification.
    is of great significance to promote the inheritance and innovation of Chinese medicine.
    fourth, ask the State Council to coordinate the introduction of more strong support policies by various ministries The State Council should actively coordinate the relevant ministries of the state, such as the State Administration of Traditional Chinese Medicine, the National Health and Health Commission, the Ministry of Industry and Information Technology, the Ministry of Science and Technology, the State Drug Administration, the State Ministry of Finance, etc., in policy to give more strong support to innovative Chinese medicine enterprises.
    It is suggested that the 14th Five-Year Plan of the pharmaceutical industry should focus on modern scientific and technological innovation in Chinese medicine, increase the support of government special funds and industry guidance funds for large varieties and innovative varieties of Chinese medicine in the areas of finance, taxation, finance, import and export, patent protection, etc., and encourage the development of innovative Chinese medicine industries by setting up special projects, venture capital guidance funds, establishing diversified investment and financing mechanisms, reducing corporate income tax, encouraging Chinese medicine enterprises to actively participate in overseas chinese medicine center projects, international organization platform projects, etc.
    The development of modern scientific and technological innovation of Chinese medicine urgently needs the strong support of national policies, stimulate the enthusiasm of Chinese medicine enterprises for research and development, the initiative of innovation firmly in their own hands, and effectively leave the ancestors of Chinese medicine to our precious wealth inherited, developed and applied well, so that Chinese medicine better benefit mankind.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.